急性髓系白血病非APL中国诊疗指南.pptVIP

* * * * * * * * Background A complete remission is essential for prolonging survival in patients with acute myeloid leukemia (AML). Daunorubicin is a cornerstone of the induction regimen, but the opt imal dose is unknown. In older pat ients, it is usual to give daunorubicin at a dose of 45 to 50 mg per square meter of body-surface area. Methods Patients in whom AML or high-risk refractory anemia had been newly diagnosed and who were 60 to 83 years of age (median, 67) were randomly assigned to receive cytara- bine, at a dose of 200 mg per square meter by continuous infusion for 7 da